The notices it replaced
2 notices since 2019, oldest first, each with its awards since FY2014.
- Posted 2019RFA-HL-20-0239 awards
- Posted 2022RFA-HL-23-01117 awards
- Posted 2024RFA-HL-26-017This notice, open · 4 awards
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 30
- 30 new
- Median first-year cost
- $553,600
- $16,596,155 in all
- Institutions
- 25
- 30 contact PIs
Awards by fiscal year
0
0
0
0
0
0
2
2
5
5
5
7
4
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- CLEVELAND CLINIC LERNER COM-CWRU2
- EMORY UNIVERSITY2
- VIRGINIA COMMONWEALTH UNIVERSITY2
- BAYLOR COLLEGE OF MEDICINE1
and 20 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-F (J1))4
- Special Emphasis Panel (ZHL1 CSR-F (O1))4
- Special Emphasis Panel (ZHL1 CSR-E (J1))3
- Special Emphasis Panel (ZHL1 CSR-E (O1))3
- Special Emphasis Panel (ZHL1 CSR-F (F1))3
and 9 other study sections
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2026 | Targeted control of mitochondrial biogenesis as a therapy for heart failure1R61HL183015-01A1 | Ghanta, Ravi KHilton, Isaac | RICE UNIVERSITY, TX | First-year cost $638,014 | Study section ZRG1 |
| FY2026 | Small Molecule Drug Discovery for Cardiac Fibrosis using AI/ML and iPSC-Derived Organoids1R61HL179715-01A1 | Pang, Paul | GREENSTONE BIOSCIENCES, INC., CA | First-year cost $625,968 | Study section ZRG1 |
| FY2026 | Small molecule therapeutics for heart failure through a reduction in the activity of tristetraprolin and improving cardiac metabolism.1R61HL179722-01A1 | Ardehali, HosseinSchiltz, Gary E | UNIVERSITY OF ARIZONA, AZ | First-year cost $562,733 | Study section ZRG1 |
| FY2026 | Recombinant hemopexin for the treatment of acute and chronic lung injury1R61HL179700-01A1 | Matalon, Sadis | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | First-year cost $519,785 | Study section ZRG1 |
| FY2025 | AAV therapies for TNNT2-associated cardiac disorders1R61HL181756-01 · under RFA-HL-23-011 | Hinson, John Travis | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | First-year cost $611,014 | Study section ZHL1 |
| FY2025 | Triple Gene Therapy for Ischemic Heart Failure1R61HL177472-01 · under RFA-HL-23-011 | Mohamed, Tamer M ARosengart, Todd K | BAYLOR COLLEGE OF MEDICINE, TX | First-year cost $560,000 | Study section ZHL1 |
| FY2025 | Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis1R61HL177451-01 · under RFA-HL-23-011 | Chen, BinLi, Xiaopeng | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | First-year cost $542,402 | Study section ZHL1 |
| FY2025 | Liposomal azithromycin to treat cardiac inflammation1R61HL177474-01 · under RFA-HL-23-011 | Abdel Latif, AhmedFeola, DavidVenditto, Vincent Joseph | UNIVERSITY OF KENTUCKY, KY | First-year cost $542,094 | Study section ZHL1 |
| FY2025 | Development of Novel RhoA Nitration Inhibitory Peptides for the Treatment of Acute Lung Injury1R61HL171783-01A1 · under RFA-HL-23-011 | Black, Stephen M | FLORIDA INTERNATIONAL UNIVERSITY, FL | First-year cost $516,250 | Study section ZHL1 |
| FY2025 | Concurrent targeting of inflammation and the inhibition of the fibrinolytic system to increase the efficacy of empyema treatment1R61HL175690-01A1 · under RFA-HL-23-011 | Komissarov, AndreySigalov, Alexander B | UNIVERSITY OF TEXAS HLTH CTR AT TYLER, TX | First-year cost $499,585 | Study section ZHL1 |
| FY2025 | Cobinamide as a disease-modifying treatment for Marfan Syndrome: optimizaation of absorption1R61HL175687-01A1 · under RFA-HL-23-011 | Boss, Gerry RDretchen, Kenneth | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | First-year cost $405,781 | Study section ZHL1 |
| FY2024 | Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling1R61HL171786-01 · under RFA-HL-23-011 | Saba, Julie D | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $565,250 | Study section ZHL1 |
| FY2024 | Small Molecule Therapeutic for Heart Failure1R61HL171717-01 · under RFA-HL-23-011 | Josyula, Vara Prasad VnPrasad, Sathyamangla V | CLEVELAND CLINIC LERNER COM-CWRU, OH | First-year cost $563,500 | Study section ZHL1 |
| FY2024 | Development of a first-in-class complement inhibitor for treating complement-mediated hematologic diseases1R61HL171747-01A1 · under RFA-HL-23-011 | Lin, Feng C | CLEVELAND CLINIC LERNER COM-CWRU, OH | First-year cost $563,500 | Study section ZHL1 |
| FY2024 | Optimizing ELD607 for Delivery by Inhalation1R61HL173911-01 · under RFA-HL-23-011 | Tarran, Robert | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | First-year cost $542,500 | Study section ZHL1 |
| FY2024 | P7C3 based small molecule for Heart failure treatment1R61HL170457-01A1 · under RFA-HL-23-011 | Tipparaju, Srinivas M. | UNIVERSITY OF SOUTH FLORIDA, FL | First-year cost $517,475 | Study section ZHL1 |
| FY2023 | Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A1R61HL161818-01A1 · under RFA-HL-23-011 | Balu-Iyer, Sathy Venkat | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | First-year cost $575,469 | Study section ZHL1 |
| FY2023 | Targeting Integrin Signaling in Atherosclerosis1R61HL168737-01 · under RFA-HL-23-011 | Biediger, Ronald JWoodside, Darren G | TEXAS HEART INSTITUTE, TX | First-year cost $572,082 | Study section ZHL1 |
| FY2023 | Small Molecule Therapeutics for Sickle Cell Anemia1R61HL163743-01A1 · under RFA-HL-23-011 | Archer, David R | EMORY UNIVERSITY, GA | First-year cost $547,199 | Study section ZHL1 |
| FY2023 | Small molecule allosteric inhibitors of PCSK9 processing to phenocopy cardioprotective genetic variants.1R61HL170383-01 · under RFA-HL-23-011 | Chorba, John S | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $537,538 | Study section ZHL1 |
| FY2023 | Optimizing function-selective ERK1/2 inhibitors for reducing AP-1-mediated airway pathology in asthma.1R61HL168723-01 · under RFA-HL-23-011 | Deshpande, Deepak AShapiro, Paul S | UNIVERSITY OF MARYLAND BALTIMORE, MD | First-year cost $524,977 | Study section ZHL1 |
| FY2022 | Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis1R61HL161804-01 · under RFA-HL-20-023 | Haak, Andrew JonHeynen-Genel, Susanne | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | First-year cost $643,499 | Study section ZHL1 |
| FY2022 | Mitigation of Exaggerated Smooth Muscle Force with Inhibitors of Integrin Alpha2Beta11R61HL163725-01 · under RFA-HL-20-023 | Jo, HyunilSundaram, Aparna Bala | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $565,250 | Study section ZHL1 |
| FY2022 | Lead identification and pre-clinical studies on allosteric inhibitors of coagulation factor XIa1R61HL161813-01 · under RFA-HL-20-023 | Desai, Umesh Ramanlal | VIRGINIA COMMONWEALTH UNIVERSITY, VA | First-year cost $543,375 | Study section ZHL1 |
| FY2022 | Novel Gene Therapy for Critical Limb Ischemia and Limb Salvage in Vascular Occlusive Disease1R61HL156152-01A1 · under RFA-HL-20-023 | Liu, Zhao-JunVelazquez, Omaida C | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | First-year cost $533,251 | Study section ZHL1 |
| FY2022 | Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant1R61HL163739-01 · under RFA-HL-20-023 | Elser, Jeremy A | SHIP OF THESEUS, LLC, PA | First-year cost $457,450 | Study section ZHL1 |
| FY2021 | Functional assay development for tafazzin enzyme replacement candidate selection1R61HL154137-01A1 · under RFA-HL-20-023 | Chin, Michael T | TUFTS MEDICAL CENTER, MA | First-year cost $623,000 | Study section ZHL1 |
| FY2021 | Targeted Identification of Dual Acting Antisickling Agents for Sickle Cell Disease Therapy1R61HL156158-01 · under RFA-HL-20-023 | Abdulmalik, Osheiza YSafo, Martin K | VIRGINIA COMMONWEALTH UNIVERSITY, VA | First-year cost $575,593 | Study section ZHL1 |
| FY2020 | Sudaxine as an analgesia sparing respiratory stimulant for use in critical care1R61HL154136-01 · under RFA-HL-20-023 | Gaston, BenjaminLewis, Stephen John | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $575,621 | Study section ZHL1 |
| FY2020 | Human iPSC-derived endothelial cells as Vascular Therapeutics1R61HL154116-01 · under RFA-HL-20-023 | Yoon, Young-Sup | EMORY UNIVERSITY, GA | First-year cost $546,000 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.